Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for Alcohol Self-Administration
NCT03645408Phase 1Terminated
- Sponsor
- Boston Medical Center
- Start
- May 2019
- Primary completion
- Jul 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of exenatide in alcohol use disorder (AUD) (2 arms), sponsored by Boston Medical Center. Primary endpoint: Alcohol Consumption at 2 hours. Started May 2019; status: terminated.
02
Drugs
exenatide
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03645408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645408.